Multi-Cancer Early Detection Tests (MCEDs) are simple blood tests that can screen for many types of cancer at once. Congress must seize the opportunity to ensure these cutting-edge tests can be covered under Medicare once they are FDA-approved and proven to have clinical benefit. Doing so has the potential to save lives and revolutionize the way we detect cancer.
of all cancer deaths come from cancers for which there are currently no proven screening tests.
of people diagnosed with cancer in the U.S. are 65 and older.
MCEDs have the potential to catch cancer, including types without current screening methods, before the disease advances. Medicare beneficiaries cannot experience unacceptable delays in access to this innovative prevention technology.
Congress must support a pathway to Medicare coverage for MCEDs once FDA-approved and clinical benefits are shown. Let’s lay the groundwork now. We can’t afford to lose another minute or risk a single life in the fight against cancer.